Pulmonary hypertension (PH) is a complex and often misunderstood condition. This article aims to demystify its intricacies, facilitating a comprehensive understanding for healthcare professionals.
PH is defined as an increase in mean pulmonary arterial pressure ≥ 25 mmHg at rest. It's classified into five groups based on etiology, clinical presentation, hemodynamic characteristics, and treatment strategy. These include pulmonary arterial hypertension, PH due to left heart disease, PH due to lung diseases and/or hypoxia, chronic thromboembolic PH, and PH with unclear multifactorial mechanisms.
The pathophysiology of PH is multifactorial, involving vasoconstriction, vascular remodeling, and in situ thrombosis. The endothelial dysfunction leads to an imbalance between vasodilators and vasoconstrictors, pro-thrombotic and anti-thrombotic factors, and cell proliferation and apoptosis. This results in increased pulmonary vascular resistance, right ventricular overload, and eventually right heart failure.
PH often presents with nonspecific symptoms such as dyspnea, fatigue, and syncope, making early diagnosis challenging. Diagnosis is confirmed through right heart catheterization, but echocardiography serves as a useful screening tool. Additional diagnostic tests include pulmonary function tests, six-minute walk test, and cardiac MRI.
Treatment strategies for PH are group-specific and aim to improve symptoms, slow disease progression, and enhance quality of life. General measures include oxygen therapy, diuretics, and anticoagulation. Specific therapies include endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs. In advanced cases, lung transplantation may be considered.
Understanding the complexities of PH is vital for its effective management. Early diagnosis, accurate classification, and appropriate treatment are key to improving patient outcomes. As healthcare professionals, it is crucial to stay abreast of the latest developments in PH to provide the best possible care to our patients.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation